Christopher D. Alafi, Director, 10% Owner at Intra-Cellular Therapies, Inc. (ITCI), bought 34,000 shares at $14.50 ($493K) on 2016-11-14, disclosed to the SEC on 2016-11-17.
Open-market purchase of $493k ITCI by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| ITCI | BUY | 2020-09-14 | $1.5M | — | Filing → |
| ITCI | BUY | 2020-09-11 | $590K | — | Filing → |
| ITCI | BUY | 2019-09-11 | $9.8M | — | Filing → |